Obinutuzumab for Primary Membranous Nephropathy

"That is accurate. The clinical trial listed on clinicaltrials.gov is currently seeking patients. The earliest posting date was June 25th, 2021 with the most recent update being October 13th, 2022. A total of 140 patients are needed for the 17 sites participating in the study."

"According to the study's eligibility requirements, patients must be aged 18 to 75 to participate. Out of the 1,001 total clinical trials, 148 are for patients under 18 and 853 are for patients over 65."

"Obinutuzumab is typically used as a treatment for nephrotic syndrome. However, it can also be effective in treating conditions such as whiplash syndrome, ophthalmia, sympathetic ophthalmia, and scalp structure."

"There is both efficacy and safety data available for Obinutuzumab, as it has gone through multiple Phase 3 trials. This gives it a score of 3."

"This clinical study is being conducted out of Penn State Univ. Milton S. Hershey Medical Center in Hershey, Pennsylvania, Accel Research Sites; Mid-Florida Kidney and Hypertension Care in Altamonte Springs, Florida, and North Shore University Hospital in Manhasset, New York. Additionally, there are 17 other locations where this trial is running."

"This medical study is looking for 140 patients that have been diagnosed with kidney disease. Participants must be between 18-75 years old and meet the following additional criteria: A diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior to or during screening, Screening urinary protein-to-creatinine ratio (UPCR) >= 5 g/g from 24-hour urine collection after best supportive care for >= 3 months prior to screening or screening UPCR >= 4 g/g after best supportive care for >= 6 months prior to screening, eGFR >= 40 mL/min"

"There are a total of 494 trials ongoing for Obinutuzumab, with 99 of them being in the critical Phase 3. Most of the research is based in Philadelphia, although there are 12293 total locations running Obinutuzumab trials."